C-reactive protein levels in schizophrenia: a review and meta-analysis.

There is an impression in the literature that schizophrenia is associated with increased inflammation, including abnormal blood levels of the acute phase reactant C-reactive protein (CRP). We performed a meta-analysis of blood CRP levels to estimate the overall effect size, as well as a pooled analysis of the prevalence of an elevated CRP level in patients with schizophrenia and related disorders. We identified articles by searching PubMed, PsycInfo, and ISI, and the reference lists of identified studies. Eight studies met the inclusion criteria for the meta-analysis, and five studies were included in the pooled analysis. CRP levels were significantly increased in patients compared to controls (effect size=0.45, 95% confidence interval 0.34-0.55, p<0.001). There was a 28% prevalence of an elevated CRP level in patients with schizophrenia and related disorders. Our results support a growing body of literature that schizophrenia is associated with increased inflammation, although many studies did not control for potential confounding factors such as BMI and smoking. Given the high prevalence of elevated CRP, metabolic syndrome, and premature cardiovascular mortality, our findings also suggest that measurement of blood CRP levels may be germane to the clinical care of patients with schizophrenia and related disorders.

[1]  D. Goff,et al.  Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia , 2007, Psychiatry Research.

[2]  Takahiro A. Kato,et al.  Cytokines and schizophrenia: Microglia hypothesis of schizophrenia , 2009, Psychiatry and clinical neurosciences.

[3]  M. Watanabe,et al.  An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives , 2006, Schizophrenia Research.

[4]  Jiang He,et al.  Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. , 2006, The American journal of medicine.

[5]  J. Ohaeri,et al.  The profile of C‐reactive proteins in functional psychotic states in a cohort in Nigeria , 1993, Acta psychiatrica Scandinavica.

[6]  M. Schwarz,et al.  The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. , 2001, Medical hypotheses.

[7]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[8]  S. Mulvagh,et al.  C-Reactive Protein and High-Sensitivity C-Reactive Protein: An Update for Clinicians , 2011, Postgraduate medicine.

[9]  R. Peña,et al.  Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia , 2007, International clinical psychopharmacology.

[10]  J. Lieberman,et al.  Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study , 2009, Biological Psychiatry.

[11]  Nagwa S. Said,et al.  C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia , 2011, Psychiatry Research.

[12]  H. Meltzer,et al.  Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs , 1997, Psychiatry Research.

[13]  V. Fernández,et al.  Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives , 2008, Schizophrenia Research.

[14]  E. Shcherbakova,et al.  The possible role of plasma kallikrein-kinin system and leukocyte elastase in pathogenesis of schizophrenia. , 1999, Immunopharmacology.

[15]  J. Vázquez-Barquero,et al.  Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample , 2010, Schizophrenia Research.

[16]  E. Severance,et al.  Differentiating nicotine- versus schizophrenia-associated decreases of the α7 nicotinic acetylcholine receptor transcript, CHRFAM7A, in peripheral blood lymphocytes , 2009, Journal of Neural Transmission.

[17]  N. Müller.  Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development , 2008, Expert opinion on therapeutic targets.

[18]  I. Melle,et al.  Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. , 2009, Bipolar disorders.

[19]  S. Saha,et al.  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? , 2007, Archives of general psychiatry.

[20]  F. Dickerson,et al.  C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia , 2007, Schizophrenia Research.

[21]  S. Beaulieu,et al.  Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin , 2007, International clinical psychopharmacology.

[22]  B. Kirkpatrick,et al.  Metabolic profile of antipsychotic-naive individuals with non-affective psychosis , 2009, British Journal of Psychiatry.

[23]  R. Pioli,et al.  Haptoglobin polymorphism and schizophrenia: Genetic variation on chromosome 16 , 2001, Psychiatry Research.

[24]  S. Beaulieu,et al.  Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial , 2007, Schizophrenia Research.

[25]  M. Leboyer,et al.  Endogenous Retrovirus Type W GAG and Envelope Protein Antigenemia in Serum of Schizophrenic Patients , 2008, Biological Psychiatry.

[26]  S. Akhondzadeh,et al.  Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial , 2007, Schizophrenia Research.

[27]  J. Danesh,et al.  C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.

[28]  K. Fehsel,et al.  Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients , 2010, International clinical psychopharmacology.

[29]  Paul M. Ridker,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein , 2009 .

[30]  M. Jakovljevič,et al.  C-reactive protein and metabolic syndrome in patients with bipolar disorder compared to patients with schizophrenia. , 2010, Psychiatria Danubina.

[31]  Jennifer L Martin,et al.  To assess, to control, to exclude: Effects of biobehavioral factors on circulating inflammatory markers , 2009, Brain, Behavior, and Immunity.

[32]  S. Djurovic,et al.  Osteoprotegerin levels in patients with severe mental disorders. , 2010, Journal of psychiatry & neuroscience : JPN.

[33]  J. Lieberman,et al.  Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III , 2005, Schizophrenia Research.

[34]  Lin He,et al.  Altered levels of acute phase proteins in the plasma of patients with schizophrenia. , 2006, Analytical chemistry.

[35]  R. Kahn,et al.  Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. , 2010, The Journal of clinical psychiatry.

[36]  H. Möller,et al.  Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. , 2002, The American journal of psychiatry.

[37]  H. Zhu,et al.  Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene , 2005, Amino Acids.

[38]  G. Reaven,et al.  Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications , 2011, International clinical psychopharmacology.

[39]  G. Fenu,et al.  Lymphocytes in schizophrenic patients under therapy: serological, morphological and cell subset findings. , 2004, Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia.

[40]  H. Möller,et al.  COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy , 2004, European Archives of Psychiatry and Clinical Neuroscience.

[41]  B. Kirkpatrick,et al.  Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects , 2011, Biological Psychiatry.

[42]  A. Boyajyan,et al.  Genetic variants of the inflammatory C‐reactive protein and schizophrenia in Armenian population: a pilot study , 2010, International journal of immunogenetics.

[43]  A. Sarandol,et al.  Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment , 2007, Journal of psychopharmacology.

[44]  H. Möller,et al.  Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment , 2010, Schizophrenia Research.

[45]  J. Suls,et al.  Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis , 2009, Psychosomatic medicine.

[46]  J. Ohaeri,et al.  Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients , 2009, Psychiatry Research.

[47]  John E. Hunter,et al.  Fixed Effects vs. Random Effects Meta‐Analysis Models: Implications for Cumulative Research Knowledge , 2000 .

[48]  R. S. Smith,et al.  The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. , 1995, Medical hypotheses.

[49]  D. Goff,et al.  Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients , 2009, Journal of clinical psychopharmacology.